Prednisolone tebutate
Blephamide, Cetapred, Chloroptic-p, Cortalone, Delta-cortef, Fernisolone-p, Hydeltra-tba, Meti-derm, Metimyd, Neo-delta-cortef, Neo-hydeltrasol, Pred, Prelone, Sterane, Sulphrin, Sulster, Vasocidin (prednisolone tebutate) is a small molecule pharmaceutical. Prednisolone tebutate was first approved as Chloroptic-p s.o.p. on 1982-01-01. It is used to treat adrenal insufficiency, ankylosing spondylitis, asthma, atopic dermatitis, and berylliosis amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
infections | D007239 |
neoplasms | D009369 |
musculoskeletal diseases | D009140 |
digestive system diseases | D004066 |
respiratory tract diseases | D012140 |
nervous system diseases | D009422 |
eye diseases | D005128 |
urogenital diseases | D000091642 |
hemic and lymphatic diseases | D006425 |
hereditary congenital and neonatal diseases and abnormalities | D009358 |
Show 7 more
Trade Name
FDA
EMA
Omnipred, Orapred, Pediapred, Pred, Pred mild (generic drugs available since 1982-01-01, discontinued: Cortalone, Delta-cortef, Econopred, Fernisolone-p, Flo-pred, Hydeltra-tba, Hydeltrasol, Inflamase, Inflamase mild, Meti-derm, Meticortelone, Metreton, Predair, Prelone, Sterane)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Gentamicin sulfate
+
Prednisolone acetate
Neomycin sulfate
+
Polymyxin b sulfate
+
Prednisolone acetate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
POLY-PRED | Allergan | N-050081 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Neomycin sulfate
+
Prednisolone sodium phosphate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
NEO-HYDELTRASOL | Merck KGaA | N-050378 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Prednisolone
Prednisolone acetate
Prednisolone acetate
+
Sulfacetamide sodium
Prednisolone sodium phosphate
Prednisolone sodium phosphate
+
Sulfacetamide sodium
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
VASOCIDIN | Novartis | N-018988 DISCN | 1988-08-26 | 1 products, RLD |
Hide discontinued
Prednisolone tebutate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
HYDELTRA-TBA | Merck KGaA | N-010562 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
blephamide | New Drug Application | 2013-11-15 |
econopred | 2006-09-11 | |
orapred | New Drug Application | 2022-02-16 |
pediapred | New Drug Application | 2020-01-29 |
prednisolone sodium phosphate | ANDA | 2023-05-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
adrenal insufficiency | — | D000309 | — |
ankylosing spondylitis | EFO_0003898 | D013167 | M45 |
asthma | EFO_0000270 | D001249 | J45 |
atopic dermatitis | EFO_0000274 | D003876 | L20 |
berylliosis | EFO_0007168 | D001607 | J63.2 |
brain neoplasms | EFO_0003833 | D001932 | C71 |
collagen diseases | — | D003095 | — |
conjunctivitis | — | D003231 | H10 |
dermatitis herpetiformis | — | D003874 | L13.0 |
edema | — | D004487 | R60.9 |
Show 19 more
Agency Specific
FDA
EMA
Expiration | Code | ||
---|---|---|---|
PREDNISOLONE, PREDNISOLONE, AUROBINDO PHARMA LTD | |||
2023-11-18 | CGT |
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Prednisolone Acetate, Flo-Pred, Taro | |||
7799331 | 2028-10-11 | DP | U-139, U-1068 |
ATC Codes
A: Alimentary tract and metabolism drugs
— A01: Stomatological preparations
— A01A: Stomatological preparations
— A01AC: Corticosteroids for local oral treatment
— A01AC54: Prednisolone, combinations
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07E: Intestinal antiinflammatory agents
— A07EA: Corticosteroids acting locally
— A07EA01: Prednisolone
C: Cardiovascular system drugs
— C05: Vasoprotectives
— C05A: Agents for treatment of hemorrhoids and anal fissures for topical use
— C05AA: Corticosteroids, topical for treatment of hemorrhoids and anal fissures
— C05AA04: Prednisolone
D: Dermatologicals
— D07: Corticosteroids, dermatological preparations
— D07A: Corticosteroid dermatological preparations, plain
— D07AA: Corticosteroids, weak (group i)
— D07AA03: Prednisolone
— D07B: Corticosteroids, combinations with antiseptics
— D07BA: Corticosteroids, weak, combinations with antiseptics
— D07BA01: Prednisolone and antiseptics
— D07C: Corticosteroids, combinations with antibiotics
— D07CA: Corticosteroids, weak, combinations with antibiotics
— D07CA03: Prednisolone and antibiotics
— D07X: Corticosteroids, other combinations
— D07XA: Corticosteroids, weak, other combinations
— D07XA02: Prednisolone
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H02: Corticosteroids for systemic use
— H02A: Corticosteroids for systemic use, plain
— H02AB: Glucocorticoids, systemic
— H02AB06: Prednisolone
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AD: Corticosteroid nasal preparations for topical use
— R01AD02: Prednisolone
— R01AD52: Prednisolone, combinations
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01B: Antiinflammatory agents, ophthalmologic
— S01BA: Corticosteroid ophthalmologic antiinflammatory agents, plain
— S01BA04: Prednisolone
— S01BB: Corticosteroids and mydriatics in combination
— S01BB02: Prednisolone and mydriatics
— S01C: Antiinflammatory agents and antiinfectives in combination
— S01CA: Corticosteroids and antiinfectives in combination, opthalmologic
— S01CA02: Prednisolone and antiinfectives
— S01CB: Corticosteroids/antiinfectives/mydriatics in combination
— S01CB02: Prednisolone
— S02: Otologicals
— S02B: Corticosteroid otologicals
— S02BA: Corticosteroids
— S02BA03: Prednisolone
— S02C: Corticosteroids and antiinfectives in combination, otologic
— S02CA: Corticosteroids and antiinfectives in combination
— S02CA01: Prednisolone and antiinfectives
— S03: Ophthalmological and otological preparations
— S03B: Corticosteroid ophthalmologic and otologic preparations
— S03BA: Corticosteroids
— S03BA02: Prednisolone
— S03C: Corticosteroids and antiinfectives in combination, opthalmologic and otologic
— S03CA: Corticosteroids and antiinfectives in combination
— S03CA02: Prednisolone and antiinfectives
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AB: Antidotes
— V03AB05: Prednisolone and promethazine
HCPCS
No data
Clinical
Clinical Trials
57 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 1 | 2 | 3 | 4 | 10 | 20 |
Alcoholism | D000437 | EFO_0003829 | F10.1 | 3 | 6 | 1 | 1 | 3 | 12 |
Suicidal ideation | D059020 | EFO_0004320 | R45.851 | — | — | — | 1 | 1 | 2 |
Dreams | D004325 | — | — | — | 1 | 1 | 2 | ||
Post-traumatic headache | D051298 | G44.3 | 1 | 1 | — | 1 | — | 2 | |
Allergic rhinitis | D065631 | J30.9 | — | — | — | 1 | — | 1 | |
Tachyphylaxis | D013618 | — | — | — | 1 | — | 1 | ||
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | 1 | — | 1 |
Portal hypertension | D006975 | EFO_0000666 | K76.6 | — | — | — | 1 | — | 1 |
Gastrointestinal hemorrhage | D006471 | K92.2 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | 2 | 1 | — | — | — | 3 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | 2 | 3 |
Combat disorders | D003130 | 1 | 1 | — | — | 2 | 3 | ||
Fibrosis | D005355 | — | 1 | — | — | — | 1 | ||
Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | 1 | — | — | — | 1 |
Alcohol withdrawal delirium | D000430 | EFO_1000800 | 1 | 1 | — | — | — | 1 | |
Problem behavior | D000066553 | — | 1 | — | — | — | 1 | ||
Traumatic stress disorders acute | D040701 | EFO_0005223 | F43.0 | — | 1 | — | — | — | 1 |
Neurogenic urinary bladder | D001750 | HP_0000011 | N31 | 1 | 1 | — | — | — | 1 |
Covid-19 | D000086382 | U07.1 | — | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 1 | — | — | — | 1 | 2 |
Healthy volunteers/patients | — | 1 | — | — | — | 1 | 2 | ||
Cigarette smoking | D000073865 | 1 | — | — | — | — | 1 | ||
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | — | — | — | — | 1 |
Anxiety | D001007 | EFO_0005230 | F41.1 | 1 | — | — | — | — | 1 |
Heart failure | D006333 | EFO_0003144 | I50 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Sleep initiation and maintenance disorders | D007319 | F51.01 | — | — | — | — | 2 | 2 | |
Wounds and injuries | D014947 | T14.8 | — | — | — | — | 1 | 1 | |
Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | — | — | 1 | 1 |
Chronic disease | D002908 | — | — | — | — | 1 | 1 | ||
Brain injuries | D001930 | S06.9 | — | — | — | — | 1 | 1 | |
Alcohol-related disorders | D019973 | F10 | — | — | — | — | 1 | 1 | |
Depression | D003863 | F33.9 | — | — | — | — | 1 | 1 | |
Cognitive dysfunction | D060825 | G31.84 | — | — | — | — | 1 | 1 | |
Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | — | — | — | 1 | 1 |
Show 5 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | PREDNISOLONE TEBUTATE |
INN | prednisolone |
Description | Prednisolone tebutate is a corticosteroid hormone. |
Classification | Small molecule |
Drug class | steroids (not prednisolone derivatives); prednisone and prednisolone derivatives |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C |
Identifiers
PDB | — |
CAS-ID | 7681-14-3 |
RxCUI | 34376 |
ChEMBL ID | CHEMBL1200909 |
ChEBI ID | 8381 |
PubChem CID | 93055 |
DrugBank | DB14632 |
UNII ID | 9PHQ9Y1OLM (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 80,949 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,338 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more